Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02536339 · ClinicalTrials.gov registry record · Phase 2
A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT02536339 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 40 participants.
The verdict
NCT02536339, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study will examine the safety and efficacy of pertuzumab in combination with high-dose trastuzumab in adult participants with HER2-positive MBC with CNS metastases and disease progression in the brain following radiotherapy.
Interventions
- DRUG Trastuzumab
- DRUG Pertuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-12-16 |
| Est. Completion | 2020-12-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02536339
The ClinicalTrials.gov registry entry for NCT02536339 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trastuzumab is the first listed.
NCT02536339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02536339 about?
NCT02536339 is a clinical study titled "A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy". This study will examine the safety and efficacy of pertuzumab in combination with high-dose trastuzumab in adult participants with HER2-positive MBC with CNS metastases and disease progression in the brain following radiotherapy.
What is the current status of trial NCT02536339?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2015-12-16. Estimated completion is 2020-12-29.
What interventions are being tested in trial NCT02536339?
The interventions under investigation include: Trastuzumab (DRUG), Pertuzumab (DRUG).
Who is sponsoring clinical trial NCT02536339?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.